Equities Analysts Issue Forecasts for Enanta Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities researchers at HC Wainwright reduced their Q3 2024 EPS estimates for shares of Enanta Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will post earnings of ($1.48) per share for the quarter, down from their previous forecast of ($0.91). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($1.49) EPS, FY2024 earnings at ($6.02) EPS, FY2025 earnings at ($5.82) EPS, FY2026 earnings at ($7.98) EPS, FY2027 earnings at ($7.02) EPS and FY2028 earnings at ($6.46) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The business had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%.

A number of other research analysts also recently issued reports on the company. JMP Securities dropped their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA opened at $12.93 on Friday. The company’s fifty day moving average price is $14.85 and its 200 day moving average price is $12.09. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $28.25. The firm has a market capitalization of $273.55 million, a P/E ratio of -2.07 and a beta of 0.54.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,281 shares in the last quarter. Clearstead Advisors LLC purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $57,000. Quantbot Technologies LP lifted its holdings in shares of Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,900 shares during the period. Sherbrooke Park Advisers LLC purchased a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $113,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals during the first quarter worth $118,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.